ReviewHormones & cancer2011
FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma.
Review in Hormones & cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Prognostic role of pretreatment [European journal of nuclear medicine and molecular imaging · 2026Article
- Morpho-Functional and Biochemical Characterization of Adrenal Masses in a Heterogeneous Cancer Population.Cancers · 2025Article
- Changing paradigms in evaluating adrenal incidentalomas: Bayesian evaluation of [World journal of clinical oncology · 2025Review
- Article
- Canadian Urological Association guideline: Diagnosis, management, and followup of the incidentally discovered adrenal mass.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2023Article
- ProminentAsia Oceania journal of nuclear medicine & biology · 2023Article
- Plant Natural Compounds in the Treatment of Adrenocortical Tumors.International journal of endocrinology · 2021Review
- Immunohistochemical Analysis of the Metabolic Phenotype of Adrenal Cortical Carcinoma.Endocrine pathology · 2020Article
- Giant nonfunctioning adrenal tumors: two case reports and review of the literature.Journal of medical case reports · 2018Review
- [Surgical strategies for non-metastatic adrenocortical carcinoma].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2018Review
- Article
- GLUT1 expression in pediatric adrenocortical tumors: a promising candidate to predict clinical behavior.Oncotarget · 2017Article
- Assessment of tumor heterogeneity in treatment-naïve adrenocortical cancer patients using (18)F-FDG positron emission tomography.Endocrine · 2016Article
- Article
- Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment.Frontiers in cell and developmental biology · 2015Review
- Impact of ¹⁸F-FDG PET/CT on the management of adrenocortical carcinoma: analysis of 106 patients.European journal of nuclear medicine and molecular imaging · 2014Article
- Giant nonfunctioning adrenocortical carcinoma: a case report and review of the literature.BMC research notes · 2014Review
- (18)F-FDG uptake at initial staging of the adrenocortical cancers: a diagnostic tool but not of prognostic value.World journal of surgery · 2013Article
- Angiogenesis Imaging of Adrenocortical Carcinoma with Ga-68-NODAGA-RGD Positron Emission Tomography: Opening New Horizons in Multimodality Imaging from Theranostic Perspective.Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, IndiaArticle
- Adrenocortical Carcinoma in Pregnancy: The First Case Report in Mexico and Review of the Literature.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adrenocortical carcinoma (ACC) is a rare tumor with aggressive behavior, high recurrence rate, and rapid evolution. Surgery is the only curative modality, while systemic treatments such as mitotane and chemotherapy associated to locoregional therapeutic tools remain as palliative options. Imaging has an important role in the management of patients with ACC both at diagnosis and during follow-up. First, it is necessary to characterize undetermined adrenal masses, selecting patients for surgery. Then, in case of malignancy, it is mandatory to assess disease extension, to detect early relapse during follow-up, and to evaluate treatment response. Computed tomography scan and magnetic resonance imaging are actually the most used techniques for these intents as they are widely available in clinical practice. (18)F-fluorodeoxyglucose positron emission tomography (FDG PET) is routinely used for other malignancies and, on the basis of published data, is also becoming a promising tool in the management of ACC. Not only is it a diagnostic tool complementary to morphological imaging in the characterization of adrenal masses and in tumoral lesions detection, but it can be also useful to evaluate tumor response to treatment. New tracers and indications for the clinical use of FDG PET in this specific disease still have to be evaluated to assess its role in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.